Use Code: ND30 And Get 30% OFF | Get Free Delivery With No Minimum Order

Frequently bought together
HYLO GEL EYE DROPS 300/DROPS 10ML
- Sku : I-015445
Key features
Hylo-Comod 0.1% Eye Drop 10 ml is an eye drop formulation containing the active ingredient sodium hyaluronate 0.1%. Sodium hyaluronate binds water and forms a viscoelastic, mucoadhesive lubricating film on the ocular surface, stabilizing the tear film and reducing friction. It is indicated for the symptomatic treatment of dry eye/keratoconjunctivitis sicca (such as burning and foreign-body sensation) and for ocular surface lubrication and protection, including after ophthalmic procedures. Available OTC as a 10 ml eye drop bottle.- Brand: HYLO
- Active Ingredient: SODIUM HYALURONATE 0.1%
- Strength: 0.1%
- Dosage Form: Eye drops
- Pack Size: 10 ml
- Route: Ophthalmic use
- Prescription Status: OTC
- Therapeutic Class: Ophthalmic
- Pharmacological Group: Ophthalmologicals
- Drug Class: Ophthalmic lubricant (artificial tears); viscoelastic tear substitute containing hyaluronic acid derivative (sodium hyaluronate).
- Manufacturer: URSAPHARMA
- Country of Origin: Germany
- SFDA Registration No.: 1203257041
- Shelf Life: 36 months
- Storage: store in a refrigerator (2°c - 8°c)
- Target Organ: Eye
- Preservative Free: Yes
Frequently bought together
Indications
Approved Uses
Symptomatic treatment of dry eye/keratoconjunctivitis sicca (e.g., burning, foreign-body sensation) due to tear film instability or environmental factors; may be used for ocular surface lubrication/protection including after ophthalmic procedures as directed.
Off-Label Uses
Adjunct ocular surface lubrication after ophthalmic surgery (e.g., refractive/cataract) and for contact lens-related dryness/discomfort (if compatible with lens use per product instructions).
Dosage & Administration
Dosing by Condition
Dry eye: Instill 1 drop into the affected eye(s) about 3 times daily; may be used more frequently as needed based on symptoms/clinician advice.
Dose Adjustment Notes
No dose adjustment is required in renal or hepatic impairment; systemic absorption is negligible with ophthalmic sodium hyaluronate.
Side Effects
Common Side Effects
Transient blurred vision immediately after instillation; mild transient burning/stinging or eye irritation/discomfort; rarely hypersensitivity reactions (e.g., itching, redness, eyelid swelling).
Side Effect Frequency
Common: transient blurred vision and mild burning/stinging/irritation after instillation. Uncommon/rare: redness, hypersensitivity reactions.
Safety & Warnings
Warnings & Precautions
Avoid contaminating the dropper tip (do not touch eye/skin/surfaces); single-user bottle; remove contact lenses if required by product instructions and reinsert after a short interval; seek medical advice if symptoms persist/worsen.
Driving Warning
Safe
Drug Interactions
Drug Interactions
No clinically significant systemic drug interactions expected; if using other ophthalmic products, separate administrations by at least 5-10 minutes and use eye ointments last.
Interaction Severity
No clinically significant systemic drug interactions expected; if using other topical eye products, separate administration by 5-10 minutes (and avoid mixing with preservative-containing drops in the same instillation).
Special Populations
Elderly
Standard adult dosing.
Kidney Impairment
No adjustment needed
Liver Impairment
No adjustment needed
Pharmacology
Mechanism of Action
Sodium hyaluronate binds water and forms a viscoelastic, mucoadhesive lubricating film on the ocular surface, stabilizing the tear film and reducing friction, thereby relieving dryness and irritation.
Onset of Action
Immediate-symptom relief typically begins within minutes of instillation.
Bioavailability
Negligible systemic bioavailability; primarily local action on the ocular surface.
Excretion
Cleared from the ocular surface mainly by tear turnover/nasolacrimal drainage; systemic excretion is not clinically relevant.
Product Information
Target Organ
Eye
Preservative Free
Yes
Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 16-07-2026
-1744229570.gif)














